Zacks Investment Research upgraded shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) from a hold rating to a buy rating in a research report report published on Tuesday. Zacks Investment Research currently has $24.00 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Separately, Jefferies Group reiterated a buy rating and issued a $28.00 price target (up from $23.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 4th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $24.75.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 22.25 on Tuesday. Supernus Pharmaceuticals has a 12-month low of $9.51 and a 12-month high of $26.84. The firm has a market cap of $1.10 billion, a P/E ratio of 45.41 and a beta of 1.86. The company has a 50-day moving average of $21.24 and a 200 day moving average of $21.37.

WARNING: “Supernus Pharmaceuticals Inc. (SUPN) Upgraded to “Buy” at Zacks Investment Research” was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The original version of this report can be read at https://www.thecerbatgem.com/2016/11/30/supernus-pharmaceuticals-inc-supn-upgraded-to-buy-at-zacks-investment-research-2.html.

In related news, CFO Gregory S. Patrick sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now owns 3,616 shares of the company’s stock, valued at $90,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.10% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Fiera Capital Corp purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $27,544,000. BlackRock Fund Advisors increased its position in shares of Supernus Pharmaceuticals by 27.5% in the third quarter. BlackRock Fund Advisors now owns 3,952,348 shares of the specialty pharmaceutical company’s stock valued at $97,742,000 after buying an additional 853,080 shares during the last quarter. Loomis Sayles & Co. L P increased its position in shares of Supernus Pharmaceuticals by 96,990.1% in the second quarter. Loomis Sayles & Co. L P now owns 763,128 shares of the specialty pharmaceutical company’s stock valued at $15,545,000 after buying an additional 762,342 shares during the last quarter. Emerald Acquisition Ltd. purchased a new position in shares of Supernus Pharmaceuticals during the second quarter valued at about $14,610,000. Finally, Bank of New York Mellon Corp increased its position in shares of Supernus Pharmaceuticals by 34.3% in the second quarter. Bank of New York Mellon Corp now owns 1,659,604 shares of the specialty pharmaceutical company’s stock valued at $33,806,000 after buying an additional 423,835 shares during the last quarter. 93.47% of the stock is currently owned by institutional investors and hedge funds.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.